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A B S T R A C T
The bioactive properties of milk and milk-products are largely attributed to the peptides
released during gastrointestinal digestion. Nevertheless, no similar studies on “Mozzarella
di Bufala Campana DOP” (MBC), the European name given to a unique protected origin des-
ignation buffalo milk product, are available so far. A novel antioxidant peptide (MBCP) after
MBC gastrointestinal digestion was identified and its in vitro intestinal protection, bioavailability,
and anti-haemolytic capacity were assayed. A 0.2 mg/mL MBCP incubation dose made H2O2-
stressed CaCo2 cell line proliferation increase by about 100%. Less than 10% hydrolysis in
the apical solution and about 10% concentration in the basolateral solution indicated for
MBCP good stability and bioavailability, respectively. A 0.2 mg/mL MBCP incubation dose
reduced H2O2-induced human erythrocyte haemolysis by 91.25%. Our data indicated MBC
as a potential functional food and MBCP as a novel food ingredient, food additive and phar-
maceutical, relevant in health promotion and disease prevention.
© 2015 Elsevier Ltd. All rights reserved.
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1. Introduction
In addition to its major nutritional role, the bioactive poten-
tial of milk is now well accepted. It has been recognised that
much of the bioactivity can be attributed not only to intact
caseins and whey proteins but also to many milk protein-derived
peptides (Korhonen, 2009). Such peptides are inactive within
the sequence of the parent protein and can be released by di-
gestive enzymes during gastrointestinal transit or by
fermentation or ripening during food processing (Kitts & Weiler,
2003). They can have a beneficial effect on a variety of biologi-
cal systems including the cardiovascular, gastrointestinal,
immune and nervous systems (Murray & FitzGerald, 2007).
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Reactive oxygen species (ROS), the by-products of oxygen
metabolism, are among the main causes of a wide range of
human degenerative pathologies, such as cardiovascular dis-
eases, diabetes, inflammation, cancer, neurodegeneration, and
accelerated aging, by a process named oxidative stress (Di
Bernardini et al., 2011; Mendis, Kim, Rajapakse, & Kim, 2007).
Peptides contribute to the body antioxidant protection. Pep-
tides occurring in the blood can on average scavenge 20% (range
10–50%) of the peroxyl radicals of plasma (Wayner, Burton,
Ingold, Barclay, & Locke, 1987). Glutathione (GSH), a tripep-
tide synthesised predominantly within the liver, mainly
scavenges free radicals and ROS (Powers & Jackson, 2008); car-
nosine, a dipeptide found in skeletal muscle, can act as a
radical scavenger and metal ion chelator (Chan, Decker, &
Feustman, 1994). Several milk-derived peptides have been found
to possess antioxidant activity (Pihlanto, 2006). Particularly,
caseinphosphopeptides (CPPs) are derived from enzymatic hy-
drolysis of casein and are rich in phosphoserine residues. The
proposed mechanism of CPP antioxidant activity is linked to
the presence of phosphate groups originating from the
phosphoserine residues in close proximity to the peptide chain
(Kitts, 2005). CPPs have been shown to possess radical scav-
enging (Chiu & Kitts, 2003) and metal chelating activity (Kim,
Jang, & Kim, 2007), whereas high amounts of CPP have been
reported to be pro-oxidative (Díaz & Decker, 2004).
Peptides can be absorbed in the intestinal tract by a number
of mechanisms including the paracellular and transcellular
routes, the lymphatic system and via basolateral transport-
ers.The molecular size and structural properties such as peptide
hydrophobicity will determine the mechanism of transport
(Segura-Campos, Chel-Guerrero, Betancur-Ancona, &
Hernandez- Escalante, 2011). Nevertheless, a bioactive peptide
may not need to be absorbed in order to elicit the antioxi-
dant function. Binding to an intestinal receptor may be sufficient
to trigger the bioactive (i.e. antioxidant) response (Xiong, 2010).
The intestine is at the interface between the organism and its
luminal environment, thus, representing a critical defence
barrier against luminal toxic agents. Therefore, in addition to
being exposed to luminal nutrients, the intestinal mucosa is
constantly challenged by diet-derived oxidants, mutagens, and
carcinogens as well as by endogenously generated ROS (Aw,
1999). Thus, antioxidant peptides may also elicit a beneficial
biological effect by reducing oxidative damage within the gas-
trointestinal tract (Xiong, 2010).
Buffalo milk is a very ancient product, typical of the tropi-
cal and sub-tropical countries, such as Southeast Asia. It is also
intensely produced in Italy, especially in the southern regions,
where it is entirely addressed to cheese making due to its high
dry residue value similar to that of sheep milk. Buffalo moz-
zarella cheese is the most famous and consumed buffalo milk
product in Southern Italy. Particularly, the so called Mozza-
rella di Bufala Campana is listed as a protected origin designation
(POD) product from the European Council [Commission Regu-
lation (EC) No.1107/1996)]. Its disciplinary of production identifies
96 municipalities in Southern Italy as the only places of pro-
duction of the so called Mozzarella di Bufala Campana DOP. It
indicates a peculiar manufacturing process that contem-
plates exclusively fresh whole buffalo milk characterised by a
specific macronutrient composition, and precise chemical–
physical and organoleptic properties of the final product.
Buffalo milk proteins have been reported to have a high ho-
mology to their cow counterparts (D’Ambrosio et al., 2008).
Nevertheless, few studies on proteins from buffalo milk and
its products as sources of bioactive peptides are available so
far. ACE-inhibitory and antimicrobial peptides after enzy-
matic digestion of buffalo milk casein have been described (De
Simone et al., 2011), while buffalo mozzarella cheese whey has
been indicated as a major source of antiproliferative and
cytomodulatory peptides (De Simone et al., 2009). Rizzello et al.
(2005) found that the peptides extracted from Italian buffalo
mozzarella cheese exhibited a specific antibacterial activity in
comparison to peptides from other cheeses. However, no studies
on bioactive buffalo mozzarella cheese peptides derived from
gastrointestinal digestion are available to date. Thus, the aim
of the present study was to evaluate the peptide production
after simulated gastrointestinal digestion of “Mozzarella di
Bufala Campana DOP” (MBC) and their potential antioxidant
activity by in vitro assays.
2. Materials and methods
2.1. Reagents and standards
All chemicals and reagents used were either analytical-
reagent or HPLC grade.The water was treated in a Milli-Q water
purification system (Millipore, Bedford, MA, USA) before use.
Chemicals and reagents used to simulate the GI digestion were:
potassium chloride (KCl), potassium thiocyanate (KSCN), mono-
sodium phosphate (NaH2PO4), sodium sulphate (Na2SO4), sodium
chloride (NaCl), sodium bicarbonate (NaHCO3), urea, α-amylase,
hydrochloric acid (HCl), pepsin, pancreatin, bile salts (Sigma
Chemical Co., St. Louis, MO, USA). Chromatographic resins
Sephadex G-50, G-25 and G-10, DPPH (1,1-diphenyl-2-
picrilhydrazyl), 2,4,6-tris-2,4,6-tripiridyl-S-triazine (TPTZ), iron
(III) chloride (dry), 6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid (Trolox), purchased from Sigma Aldrich (Sigma
Chemical Co.). All organic solvents were purchased from Carlo
Erba (Milano, Italy). 2′,7′-Dichlorofluorescin diacetate (DCFH-
DA, Sigma Chemical Co.) was dissolved in dimethylsulphoxide
(DMSO) to obtain 100 mM stock solution (aliquoted and stored
at −20 °C). Work solutions of DCFH-DA were produced by di-
luting aliquots in 1% phosphate buffer saline (PBS, 10 mM,
pH 7.4) at different concentrations.
2.2. Sample collection and preparation
“Mozzarella di Bufala Campana DOP” (MBC) was purchased in
Caserta (Campania, Italy) in a local dairy. An aliquot (250 g),
approximately 1 h after its preparation, was stored at −80 °C.
Sample was freeze-dried and, then, subjected to lipid extrac-
tion according to AOAC (1995) method 948.16, by using a 6-place
units Extraction Unit E-816 Soxhlet (Buchi, Flawil, Switzer-
land). After centrifugation at 3000 g for 5 min, pellets were
transferred into a pre-weighed scintillation vial, dried under
nitrogen, and kept at −80 °C until analyses.
2.3. In vitro gastrointestinal digestion
The assay was performed according to the procedure de-
scribed by Raiola, Meca, Mañes, and Ritieni (2012), with slight
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modification. GI digestion was distinguished into salivary, gastric
and duodenal digestive steps. For the salivary digestion, de-
fatted sample (80.5 g) was mixed with 6 mL of artificial saliva
composed of: KCl (89.6 g/L), KSCN (20 g/L), NaH2PO4 (88.8 g/L),
Na2SO4 (57.0 g/L), NaCl (175.3 g/L), NaHCO3 (84.7 g/L), urea
(25.0 g/L) and 290 mg of α-amylase. The pH of the solution was
adjusted to 6.8 with 0.1 M HCl. The mixture was introduced in
a plastic bag containing 40 mL of water and homogenised in
a Stomacher 80 Microbiomaster (Seward, Worthing, UK) for
3 min. Immediately, 0.5 g of pepsin (14,800 U) dissolved in HCl
0.1 N was added, the pH was adjusted to 2.0 with 6 M HCl, and
then incubated at 37 °C in a Polymax 1040 orbital shaker
(250 rpm) (Heidolph, Schwabach, Germany) for 2 h. After the
gastric digestion, the pancreatic digestion was simulated as
follows: the pH was increased to 6.5 with 0.5 M NaHCO3 and
then 5 mL of a mixture pancreatin (8.0 mg/mL) and bile salts
(50.0 mg/mL) (1:1; v/v), dissolved in 20 mL of water, were added
and incubated at 37 °C in an orbital shaker (250 rpm) for 2 h.
Intestinal digested sample was freeze-dried and stored at −80 °C
until further analysis.
2.4. Gel filtration chromatography of MBC
gastrointestinal digest
2.4.1. Fraction separation
The freeze-dried intestinal digested sample was dissolved with
water (50 mg/mL) and purified on a Sephadex G-50 gel filtra-
tion column (2 × 75 cm), by eluting with distilled water at
0.5 mL/min. Aliquots (3 mL) were collected and pooled into frac-
tions by monitoring absorbance at 280 nm. Fractions were
lyophilised, dissolved with water (4 mg/mL), and analysed for
their antioxidant properties (see Section 2.4.2). The most active
fraction was lyophilised, dissolved with water (50 mg/mL), and
loaded on a Sephadex G-25 gel filtration column (2 × 75 cm),
by eluting, monitoring, and pooling into fractions as de-
scribed earlier. Similarly, the fraction with the highest
antioxidant activity was further purified on a G-10 gel filtra-
tion column (2 × 75 cm), by eluting, monitoring, and pooling into
fractions as described earlier. The most antioxidant fraction
was analysed by RP-HPLC (see Section 2.4.3).
2.4.2. Fraction antioxidant activity
For each antioxidant assay, a trolox aliquot was used to develop
a 50–500 µmol/L standard curve. All data were then expressed
as Trolox Equivalents (µmol TE/100 mL).
2.4.2.1. DPPH•-scavenging assay. The test was performed ac-
cording to Brand-Williams, Cuvelier, and Berset (1995). Fraction
aliquots (20 µL) were added to 3 mL of DPPH solution
(6 × 10−5 mol/L) and the absorbance was determined at 515 nm
every 5 min until the steady state.
2.4.2.2. Ferric reducing antioxidant power (FRAP) assay. The
assay was performed as previously described (Benzie & Strain,
1996). A solution of 10 mmol/L TPTZ in 40 mmol/L HCl and
12 mmol/L ferric chloride was diluted in 300 mmol/L sodium
acetate buffer (pH 3.6) at a ratio of 1:1:10. Fraction aliquots (20 µL)
were added to 3 mL of the FRAP solution and the absorbance
was determined at 593 nm every 5 min until the steady state.
2.4.3. Fraction purity evaluation
Sephadex G-10 fraction showing the strongest antioxidant ca-
pacity was filtered through a Phenex-PVDF 17 mm Syringe Filter
0.45 µm (Phenomenex, Torrance, CA, USA) and analysed by RP-
HPLC. Analyses were run on a Finnigan HPLC system (Thermo
Electron Corporation, San Jose, CA, USA) provided with pho-
todiode array detector (DAD). The column selected was an
Aeris PEPTIDE 3.6 µm XB-C18 New Column 250 × 4.6 mm
(Phenomenex). Elution conditions consisted in 2% acetic acid
(solvent A) and 2% acetic acid in methanol (solvent B) gradi-
ent at a flow rate of 1.0 mL/min. The gradient conditions were:
0–20 min, 0–100% B; 20–23 min, 100% B; 23–27 min, 0% B, fol-
lowed by 5 min of maintenance. Chromatograms were recorded
at 280 nm and indicated that the fraction analysed was a high
purity peptide (96%), that was named as MBCP and subjected
to characterisation.
2.5. Characterisation of MBCP
MBCP was collected, and its purity and molecular weight were
determined by ultra performance liquid chromatography
electrospray ionisation tandem mass spectrometry (UPLC ESI–
MS/MS). A Waters ACQUITY UPLC system (Waters Corporation,
Milford, MA, USA), coupled with a Synapt Mass Quadrupole
Time-of-Flight Mass Spectrometer (UPLC-ESI Q-TOF MS) (Waters
Corporation), was used to identify the purified peptide.
MBCP was dissolved in mobile phase, and 5 µL of peptide so-
lution was loaded onto an ACQUITY BEH C18 column
(100 mm × 2.1 mm, 1.7 µm) (Waters Corporation). Elution con-
ditions consisted in 0.5% acetic acid (eluent A) and methanol
(eluent B) gradient at a flow rate of 0.3 mL/min. The gradient
conditions were: 0–3 min, 5% B; 3–15 min, 5%–30% B; 15–17 min,
30% B. Following molecular mass determination, the peptide
was automatically selected for fragmentation, and sequence
information was obtained by tandem mass spectroscopy analy-
sis. MS/MS analyses were performed in the positive electrospray
ionisation mode by using CID. Collision energy was selected
from 10 to 35 eV. Argon was introduced as the collision gas at
a pressure of 10 psi. Sequencing of peptide was acquired over
the m/z range 50–2000 using the Biolynx software.
2.6. Gel filtration chromatography of non-digested MBC
protein extract
In order to ascertain the presence of MBCP in the non-digested
MBC, a MBC aliquot (250 g) was subjected to preparation as de-
scribed in Section 2.2. Then, the prepared sample was purified
as described in Section 2.4 and fraction characterisation was
performed as described in Section 2.5.
2.7. Peptide synthesis
MBCP was synthesised using the solid-phase method and pu-
rified via HPLC after deprotection. Synthetic peptide was used
to confirm MBCP identity. Both synthetic and isolated MBCP
were used for in vitro assays and results were compared.
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2.8. CaCo2 cell line tests
2.8.1. Cell culture and proliferation assay
The assay was performed according to previous authors (De
Simone et al., 2009). CaCo2 cells (American Type Culture Col-
lection, Rockville, MD) were grown in HEPES buffered Dulbecco’s
modified Eagle’s medium (DMEM) with 4.5 g/L glucose and
supplemented with 12.5% fetal calf serum (FCS) (Flow, McLean,
VA, USA), 1% (v/v) MEM non-essential amino acids, 5 mM
L-glutamine, 1% sodium pyruvate, 40 U/mL penicillin, 100 µg/mL
gentamycin, and 40 µg/mL streptomycin (DMEMc). The cells
(17–21 passages) were grown in a humidified atmosphere of
CO2/air (5:95) at 37 °C and were plated in 12 multi-well plates
at different densities. After incubation for 4 h, the cells were
washed with PBS to remove unattached dead cells. The cells
were pre-treated for 30 min with 50 µM H2O2 in PBS solution
(H-CaCo2). Then, the pre-confluent H-CaCo2 (21 passages) cells
were seeded in 12 multi-well plates and incubated at 37 °C for
24 h with 0.0125–1 mg/mL of MBCP in water solution. The cell
number was measured with a haemocytometric counter and
cell proliferation was evaluated by CyQuant® cell prolifera-
tion assay Kit (InvitrogenTM) (Thermo Fisher Scientific, San Jose,
CA, USA) with dye fluorescence measurement at 480 nm ex-
citation maximum and 520 nm emission maximum.The control
sample consisted in H-CaCo2 cells not added of peptide (un-
treated cells). Cell proliferation was expressed in percentage
of proliferation compared with the control. All experiments were
performed on triplicate cultures.
2.8.2. Preparation of cell extract
The assay was performed as previously described (Tenore et al.,
2014). H-CaCo2 cells were collected by centrifugation and then
resuspended in ice-cold 50 mM potassium phosphate buffer
(pH 7.4), containing 2 mM ethylenediaminetetraacetic acid
(EDTA). The cells were sonicated, followed by centrifugation at
13,000 × g for 10 min at 4 °C. The resulting supernatants were
collected and kept on ice for immediate measurements, to be
described later.
2.8.3. Measurement of intracellular ROS accumulation
The assay was performed as previously described
(Gomez-Monterrey et al., 2013). The thiobarbituric acid reac-
tive substance (TBARS) assay was performed on membranes
extracted from Caco-2 and H-Caco2 cells after 48 h incubation
with 0.0125–1 mg/mL of MBCP in water solution, and from the
untreated control cells, using an ice-cold lysis buffer (50 mM
Tris, 150 mM NaCl, 10 mM EDTA, 1%Triton) supplemented with
a mixture of protease inhibitors. The homogenate was centri-
fuged at 1200 × g for 10 min to separate the cytosol (supernatant)
from the membranes (pellet).The pellet was dissolved in 50 mM
Tris,150 mM NaCl,and 10 mM EDTA.Aliquots (10 µL) of the mem-
brane preparation were added to 2 mL thiobarbituric acid (TBA)
trichloroacetic acid (TCA) (15% TCA, 0.3% TBA in 0.12 M HCl)
solution at 100 °C for 30 min.The reaction was stopped by cooling
the sample in cold water. The samples were centrifuged at
5000 × g for 10 min and the chromogenic (TBARs) was quan-
tified by spectrophotometry at a wavelength of 532 nm. The
quantity of TBARs was expressed as µM/µg proteins.
2.8.4. Measurement of cellular superoxide dismutase activity
The assay was performed as previously described (Tenore et al.,
2014). Total cellular superoxide dismutase (SOD) activity was
measured as follows (Kirshenbaum & Singal, 1992). Briefly, a
reaction mixture contained 50 mM potassium phosphate buffer
(pH 7.8), 1.33 mM diethylenetriaminepentaacetic acid, 1.0 U/mL
catalase, 70 µM nitroblue tetrazolium, 0.2 mM xanthine, 50 µM
bathocuproinedisulphonic acid, and 0.13 mg/mL bovine serum
albumin (BSA). A 0.8 mL aliquot of the reaction mixture was
added to each cuvette, followed by addition of 100 µL of lysate.
The cuvettes were pre-warmed at 37 °C for 3 min. The forma-
tion of formazan blue was monitored at 560 nm, 37 °C for 5 min.
The sample total SOD activity was calculated using a concur-
rently run SOD (Sigma) standard curve, and expressed as units
per mg of cellular protein. Cellular protein content was quan-
tified with Bio-Rad protein assay dye (Hercules, CA) based on
the method which makes use of BSA as the standard.
2.9. In vitro intestinal transepithelial transport studies
The assay was performed as previously described (Tenore et al.,
2014).The human colon carcinoma cell line CaCo2 (HTB-37) was
obtained from the American Type Culture Collection (LGC
Promochem, Molsheim, France). Cells were cultured (17–21 pas-
sages) in HEPES buffered Dulbecco’s modified Eagle’s medium
(DMEM) with 4.5 g/L glucose and supplemented with 12.5% fetal
calf serum (FCS),1% nonessential amino acids,5 mM L-glutamine,
40 U/mL penicillin, 100 µg/mL gentamycin, and 40 µg/mL strep-
tomycin (DMEMc). Cells were maintained at 37 °C in a humidified
atmosphere of CO2/air (5:95, v/v) and passaged every 7 days by
trypsinisation.They were seeded inTranswell (Transwell® inserts
of 3 µm pore size and 24 mm diameter) at 6 × 104 cells/cm2.The
medium (15 mL DMEM containing 12.5% FCS) was changed every
2 days until cells reached confluence (7–8 days).The integrity of
the monolayers (cultured for 14–15 days) was evaluated by mea-
surement of the transepithelial electrical resistance (TEER) using
a Millicell-ERS device (Millipore, Zug, Switzerland). Only CaCo2
monolayers showing TEER higher than 300 Ω × cm2 were used
for the experiments.The integrity of the monolayers was checked
before,during and after the experiment.Then,CaCo2 cells mono-
layers were gently rinsed twice with PBS, medium was removed
from the apical and basal sides of the cultures, transport medium
(TM, Hank’s balanced salt solution supplemented with 25 mM
glucose and 10 mM HEPES) was added to the apical (2 mL) and
to the basolateral (2 mL) compartments, and pH was adjusted
to 6 or 7.4.After 30 min of incubation, medium at the apical side
was replaced with freshTM containing MBCP 0, 0.5, 1, 2 or 4 mM.
After 4 h of incubation at 37 °C, apical and basal solutions were
collected, and aliquots (5 mL) were filtered on Phenex-PVDF
17 mm Syringe Filter 0.45 µm (Phenomenex, Torrance, CA).
Samples were stored at −20 °C until LC–MS/MS analyses to
measure the concentration of MBCP in both compartments (for
LC–MS/MS operating conditions, see Section 2.5).
2.10. Human erythrocyte test
2.10.1. Haemolysis inhibition assay
The inhibitory capacity of MBCP on erythrocyte haemolysis was
determined according to the procedures reported by Helmerhorst,
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Reijnders, van’t Hof, Veerman, and Nieuw Amerongen (1999) with
slight modification. Blood was obtained from healthy volun-
teers. The experiment was carried out in accordance with the
guidelines issued by the Ethical Committee of the Istituto
Superiore di Sanità (2003). Erythrocytes were separated from
plasma by centrifuging at 1200 g for 10 min at 4 °C, and washed
three times with PBS.Then, erythrocyte suspension (0.2 mL, 20%,
v/v, dissolved with PBS) was mixed with MBCP solution (0.2 mL,
0.1–2 mg/mL), and was gently shaken and incubated at 37 °C for
30 min. At the end of incubation, 0.2 mL of 100 mM H2O2 in PBS
solution was added.The mixture was further incubated at 37 °C
for 2 h. After incubation, the mixture was diluted with 3.2 mL
PBS (pH 7.4). After centrifuging at 1200 g for 10 min at 4 °C, the
absorbance of the supernatant was read at 540 nm.Distilled water
was used as control. The inhibition of erythrocyte haemolysis
was calculated as (1-Asample 540/Acontrol 540) × 100%.
2.10.2. Effect on intracellular ROS generation
In order to clarify the anti-haemolytic mechanisms, the po-
tential effects of MBCP against H2O2-induced oxidative stress
in human erythrocytes were evaluated.
Erythrocyte suspension was obtained and incubated with
MBCP solutions as described in Section 2.10.1. After addition of
0.2 mL of 100 mM H2O2 in PBS solution and incubation at 37 °C
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Fig. 1 – Chromatographic isolation of MBCP. (A) Fractionation of MBC gastrointestinal digest by Sephadex G-50 gel filtration
chromatography; (B) fractionation of fraction B by Sephadex G-25 gel filtration chromatography; (C) fractionation of fraction
3 by Sephadex G-10 gel filtration chromatography; (D) RP-HPLC analysis of fraction III. MBC: “Mozzarella di Bufala Campana
DOP”; MBCP: “Mozzarella di Bufala Campana DOP” peptide.
Table 1 – Near equilibrium steady state antioxidant
capacity of size exclusion chromatographic fractions
from MBC intestinal digesti.
Fractions Assay method
DPPH FRAP
Sephadex G-50*
A 137.53 ± 2.10a 98.25 ± 1.86a
B 161.39 ± 2.61b 125.77 ± 1.72b
Sephadex G-25**
1 157.53 ± 1.93c 120.18 ± 2.76c
2 143.09 ± 3.11d 112.43 ± 2.16d
3 163.98 ± 2.72e 126.37 ± 2.58e
Sephadex G-10***
I 139.09 ± 3.21f 102.43 ± 2.35f
II 129.64 ± 2.83g 86.59 ± 1.96g
III 164.84 ± 3.25h 114.76 ± 1.93h
* The concentration of all fractions was 4 mg/mL.
** The concentration of all fractions was 0.1 mg/mL.
*** The concentration of all fractions was 0.05 mg/mL.
a,b,c,d,e,f,g,h Mean values in columns with different superscript letters
are significantly different by the Tukey–Kramer multiple comparison
test ( P < 0.05).
i Expressed as TEs (µmol/L) of fractions measured by FRAP and DPPH
assays at the steady state (DPPH, 45 min; FRAP, 55 min). Data are
mean values ± SD (n = 5; P < 0.05).
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for 2 h, the mixture was centrifuged at 1200 g for 10 min at 4 °C.
The residue erythrocytes were washed 3 times with PBS (pH 7.4)
and re-suspended with 5 volumes of PBS (pH 7.4). An aliquot
(100 µL) of erythrocytes suspension was firstly centrifuged at 1200 g
for 10 min at 4 °C and the supernatant was discarded.Then,DCFH-
DA (200 µL, 10 µmol/L) was added to suspense the erythrocytes.
After incubation at 37 °C for 25 min in the dark, the mixture was
washed with PBS to completely remove the DCFH-DA outside
the erythrocytes. At the end of washing, the erythrocytes con-
taining the fluorescent probe were re-suspended with 600 µL PBS.
Intracellular ROS generation was measured by recording the fluo-
rescence intensity of erythrocytes by aVarioskan Flash Spectral
Scan Multimode Plate Reader (Thermo Fisher Scientific,Waltham,
MA), with the excitation and emission wavelengths at 485 and
525 nm, respectively. PBS-treated erythrocytes were considered
as the blank control with 100% of the fluorescence intensity.The
results were reported as the percentage of DCF fluorescence in-
tensity of control (% control) calculated as following: DCF
Fluorescence (% control) = Fsample × 100%/Fblank,where Fsample
and Fblank represent the fluorescence intensity of sample and
blank control, respectively.
2.11. Statistics
Unless otherwise stated, all of the experimental results were
expressed as mean ± standard deviation (SD) of at least five rep-
lications. Statistical analysis of data was performed by Student’s
t test or two-way ANOVA followed by the Tukey–Kramer multiple
comparison test to evaluate significant differences between a
pair of means. The level of significance (α-value) was 95% in
all cases (P < 0.05).
3. Results and discussion
3.1. Isolation and identification of MBC peptides after
gastrointestinal digestion
The gel filtration chromatography was used for the fraction-
ation of MBC intestinal digest. Two fractions (fractions A and
B) were obtained from Sephadex G-50 column (Fig. 1A) and their
antioxidant activity was evaluated. Since natural antioxidants
are characterised by complex reactivity and different
Fig. 2 – Q-TOF MS analysis of MBCP. (A) Molecular mass of MBCP; (B) fragmentation pattern of ion at m/z 1326.5. MBCP:
“Mozzarella di Bufala Campana DOP” peptide.
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mechanisms of action, the antioxidant capacity of food and
food extracts cannot be assessed by using a single method
(Schlesier, Harwat, Bohm, & Bitsch, 2002). Then, two different
spectrophotometric assays, DPPH and FRAP tests, were ex-
ecuted, and antioxidant activities were expressed as trolox
equivalents (TEs). The sample ability to scavenge free radi-
cals is indicated by the decrease in DPPH absorption, while the
FRAP test evaluates the reducing power of sample constituents.
As shown in Table 1, all the fractions showed antioxidant
capacity, and fraction B exhibited the highest values. Frac-
tion B was further purified on a Sephadex G-25 column (Fig. 1B)
to obtain three fractions (fractions 1–3). The most active one
(fraction 3) was further fractionated on Sephadex G-10 column
(Fig. 1C) to yield three fractions (fractions I–III) (Table 1). Frac-
tion III showed the strongest antioxidant capacity (Table 1) and
was chosen to be further purified by HPLC. As shown in Fig. 1D,
HPLC analysis showed four peaks of which peak at Rt 23.4 min
represented about 96% of the fraction. Thus, HPLC analysis in-
dicated that fraction III was a high purity peptide that was
named as MBCP and subjected to characterisation.
Q-TOF MS analysis indicated for MBCP a molecular mass
of 1326.5 Da (Fig. 2A).The observed molecular mass was in agree-
ment with the calculated molecular mass of the peptide. MS/MS
analysis (Fig. 2B) showed that the major sequence of MBCP was
Cys-Lys-Tyr-Val-Cys-Thr-Cys-Lys-Met-Ser (CKYVCTCKMS),
which was referred to a novel peptide, in accordance to data-
bases available online (http://www.prospector.ucsf.edu;
http://www.expasy.ch).
Pure MBCP was used as external standard for HPLC–DAD
quantitative analysis. A stock solution was prepared in water
and dilutions were made to cover a concentration range of 0.012–
0.36 mg/mL. MBCP was quantified as 180.89 mg/100 g MBC fw.
In order to ascertain the presence of MBCP in the non-
digested MBC, a MBC aliquot (250 g) was subjected to
preparation, purification, and fraction characterisation, as re-
ported earlier. The absence of such peptide in the native MBC
corroborated the hypothesis that MBCP was the enzymatic
product of MBC simulated GI digestion.
3.2. MBCP effects on H2O2-stressed CaCo2 cell lines
CaCo2 cell lines derived from human intestinal epithelial ad-
enocarcinoma are regarded as a suitable model system for the
in vitro evaluation of intestinal functions and nutrient
absorption. Particularly, they are reported to reproduce several
of the normal physiological responses to various modulatory
agents, in a model which mimics the damages deriving from
exposition to endogenous and exogenous oxidative agents (Levy,
Mehran, & Seidman, 1995).
Thus, the potential protective effects of MBCP against H2O2-
induced oxidative stress in CaCo2 cell lines were evaluated. Cells
were exposed to 50 µM H2O2 for 30 min (H–CaCo2) and then
treated for 24 h with 0.0125 to 1 mg/mL of MBCP. A linear cor-
relation between incubation dose and cell proliferation was
revealed, and the maximum result was achieved with a
0.2 mg/mL MBCP dose which made the stressed cell line pro-
liferation increase by about 100% (Fig. 3A). We examined the
effect on free radical and manganese superoxide dismutase
levels in the stressed cell line exposed to increasing doses
(0.0125–1 mg/mL) of MBCP (Fig. 3B). Our data demonstrated that
MBCP at a maximum dose of 0.2 mg/mL was able to directly
scavenge free radicals without interfering with cell antioxi-
dant defensive system involving enzymes and proteins for
self-protection.
The structure–function relationship and the mechanism of
peptide-induced antioxidant activity have not been fully elu-
cidated. The mechanism of action has been referred to
the physicochemical properties of the peptide quali-quantitative
amino acid profile. As regards our peptide composition, amino
acids, such as Tyr, Met, Lys, and Cys, are generally accepted to
be antioxidants (Wang & Gonzalez de mejia, 2005). Particu-
larly, residues with an aromatic ring structure (such as Tyr) can
donate a proton to electron deficient radicals, while non-
polar residues (Val and Met) can enhance the solubility of
peptides in a lipid matrix improving the accessibility to
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(A) Enhancement of cell proliferation; (B) protection against
H2O2-induced ROS generation. MBCP: “Mozzarella di Bufala
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hydrophobic radical species or polyunsaturated fatty acids
(Power, Jakeman, & FitzGerald, 2013). Further structural prop-
erties, which are important predictors of a peptide antioxidant
activity, refer to the polar domain of the C terminal amino acid,
and the low hydrophobicity, together with steric hindrance, of
the second amino acid adjacent to the C terminus. These
aspects make amino acids, such as Ser and Met, respectively,
frequently present in these positions (Power et al., 2013). Nev-
ertheless, the sulphydryl (R-SH) group in Cys has a unique
antioxidant activity and interacts with the radical species by
hydrogen donation from the SH group (Elias, Kellerby, & Decker,
2008).
All of the reported results were in full agreement with those
obtained by performing the same assays on the synthetic
MBCP.
3.3. In vitro MBCP intestinal stability and bioavailability
The intestinal stability and bioavailability of MBCP were evalu-
ated by using single layers of CaCo2 cells as a model of
absorption in the small intestine.
LC–MS analysis highlighted no significant hydrolysis (less
than 10%) of MBCP in the apical solution by the brush border
exopeptidases after 120 min incubation and regardless of the
peptide concentration (Fig. 4A). LC–MS analysis of basolateral
solution revealed that MBCP was absorbed intact through CaCo2
monolayer, with a concentration-dependent transport follow-
ing a saturable pattern described by a linear curve (Fig. 4B). For
LC–MS operating conditions, see Section 2.5. Interestingly, the
actual amount of MBCP transepithelially transported was about
10%, thus, higher than what generally reported for different
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size (3–17 amino acid units) and polarity peptides transported
from CaCo2 monolayer apical to basolateral side (Pauletti,
Okumu, & Borchardt, 1997; Regazzo et al., 2010; Satake et al.,
2002).Among the many different transport pathways, the carrier-
mediated transport systems, such as the H+-coupled PepT1
transporter, may be excluded as main pathway involved in the
transport of MBCP since they are active and saturable symporters
specific for intestinal absorption of charged di- and tripeptides
(Brandsch, Knutter, & Bosse-Doenecke, 2008).The average polar
properties of MBCP would also exclude a possible passive
transcellular diffusion since a vesicular-mediated internalisation,
the main mechanism involved, would imply absorption by apical
cell membrane through hydrophobic interactions (Knipp, Velde,
Siahaan, & Borchardt, 1997). Actually, the low level of degra-
dation of MBCP during its transepithelial transfer strongly
corroborates that passive transcellular diffusion would not be
the main pathway involved in its transport. Nevertheless, the
capacity of amino acids to form hydrogen bonds with lipid phos-
phates of cell membranes, like that of most of MBCP amino
acid moieties (Cys, Lys, Tyr, Thr, Ser), has been described as a
main physicochemical feature favoring the translocation process
via transcytosis route (Pauletti et al., 1996), so that the passive
diffusion would not be completely excluded. Overall, a pos-
sible involvement of the paracellular route in the transport of
MBCP could be hypothesised. In fact, the passive paracellular
transport via tight junctions has been usually reported to be
normally applicable to the absorption of water soluble low-
molecular-weight and short-chain peptides and, in general, it
is specific for positively charged molecules because tight junc-
tions are on average negatively charged (Salamat-Miller &
Johnston, 2005).
All of the reported results were in full agreement with those
obtained by performing the same assays on the synthetic MBCP.
3.4. MBCP effects on H2O2-induced human
erythrocyte haemolysis
Since a significant amount (about 10%) of MBCP was shown
to be transported from CaCo2 monolayer apical to basolateral
side, MBCP would be expected to be potentially able to reach
blood circulation and exert systemic effects. Primary targets
could be red blood cells; interestingly, recent studies have re-
ported on both erythrocyte protecting and haemolytic capacities
of food deriving peptides (Ghribi et al., 2015; Hong, Chen, Hu,
& Wang, 2014; Xue et al., 2009).
MBCP was observed to possess a strong ability to inhibit H2O2-
induced human erythrocyte haemolysis (Fig. 5A).The inhibition
ratio was 41.38% at 0.1 mg/mL of MBCP, and reached 91.25% when
the concentration increased to 2.0 mg/mL. The estimated half-
inhibitory concentration (IC50) was 0.12 ± 0.01 mg/mL.
In order to clarify the anti-haemolytic mechanisms, the po-
tential effects of MBCP against H2O2-induced oxidative stress
in human erythrocytes were evaluated. The nonpolar DCFH-
DA was used as a probe to investigate the generation of ROS.
DCFH-DA can rapidly diffuse into cells and is hydrolysed by
cellular esterases into DCFH. The intracellular DCFH can be
easily oxidised by free radicals into fluorescent DCH. The fluo-
rescence intensity increases with the increase of intracellular
ROS (Wolfe & Liu, 2007). Our data clearly indicated for MBCP
a significant capacity to counteract H2O2-induced oxidative
stress in red blood cells (Fig. 5B). Particularly, ROS generation
was reduced by 43.28% at 0.1 mg/mL of MBCP, and reached
92.18% when the concentration increased to 2.0 mg/mL.
All of the reported results were in full agreement with those
obtained by performing the same assays on the synthetic MBCP.
4. Conclusions
The present study indicated MBC as a good source of bioactive
peptides after GI digestion. Specifically, a novel antioxidant
peptide (MBCP) was detected in the intestinal digest and its
in vitro intestinal protection, bioavailability, and anti-haemolytic
capacity were assayed. A potential intestinal protection against
induced oxidative stress was revealed. MBCP demonstrated a
good stability to brush border exopeptidases and a surpris-
ingly higher bioavailability than what generally reported by in
vitro experiments for different sizes and polarity peptides. Con-
cerning the significant amount of MBCP transepithelially
transported, MBCP would be expected to be potentially able to
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Fig. 5 – Protective effect of MBCP against H2O2-induced
human erythrocyte haemolysis. (A) Inhibition of
erythrocyte haemolysis; (B) effect on ROS generation in
erythrocytes. MBCP: “Mozzarella di Bufala Campana DOP”
peptide. Values are expressed as means ± SD (n = 5;
P < 0.05). abcdMean values with different superscript letters
are significantly different by the Tukey–Kramer multiple
comparison test. Ctrl: untreated cell lines.
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reach blood circulation and exert systemic effects. According
to recent studies reporting on erythrocyte protecting capaci-
ties of food deriving peptides, MBCP was observed to possess
a strong ability to inhibit H2O2-induced human erythrocyte
haemolysis. Our experimental results would suggest MBC as
a potential functional food and MBCP as a novel food ingre-
dient, food additive and pharmaceutical, relevant in health
promotion and disease risk reduction.
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